Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PTT003
MIFTS: 42

Pituitary-Dependent Cushing's Disease

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Pituitary-Dependent Cushing's Disease

About this section

MalaCards integrated aliases for Pituitary-Dependent Cushing's Disease:

Name: Pituitary-Dependent Cushing's Disease 12 15 73
Pituitary-Dependent Cushing Disease 12
Pituitary Acth Hypersecretion 44
Overproduction of Acth 12

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3946
ICD10 33 E24.0
MeSH 44 D047748
NCIt 50 C113210
SNOMED-CT 68 190502001 9545009
UMLS 73 C0221406
Sources

Summaries for Pituitary-Dependent Cushing's Disease

About this section
MalaCards based summary : Pituitary-Dependent Cushing's Disease, also known as pituitary-dependent cushing disease, is related to acth-secreting pituitary adenoma and bronchus adenoma. An important gene associated with Pituitary-Dependent Cushing's Disease is SST (Somatostatin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Corticotropin-releasing hormone signaling pathway. The drugs Somatostatin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Sources

Related Diseases for Pituitary-Dependent Cushing's Disease

About this section

Diseases related to Pituitary-Dependent Cushing's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 acth-secreting pituitary adenoma 33.1 CRH POMC PRL
2 bronchus adenoma 11.0 POMC SST
3 acidophil adenoma 11.0 POMC SST
4 tsh producing pituitary tumor 10.9 PRL SST
5 generalized resistance to thyroid hormone 10.9 PRL TRH
6 pituitary adenoma 1, multiple types 10.8 PRL SST
7 pituitary adenoma 4, acth-secreting 10.8
8 prolactin producing pituitary tumor 10.8 PRL SST
9 ectopic cushing syndrome 10.8 CRH POMC SST
10 pseudohypoparathyroidism, type ia 10.8 PRL TRH
11 pituitary tumors 10.7 POMC PRL SST
12 adenohypophysitis 10.7 POMC PRL TRH
13 suprasellar meningioma 10.7 POMC TRH
14 endometriosis of uterus 10.7 GNRH1 PRL
15 scleredema adultorum 10.7 INS POMC
16 sella turcica neoplasm 10.7 GHRH POMC PRL
17 acth deficiency, isolated 10.7 CRH POMC
18 tuberculum sellae meningioma 10.7 GHRH POMC PRL
19 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.7 CYP21A2 POMC
20 hypogonadotropism 10.6 GNRH1 PRL
21 acute adrenal insufficiency 10.6 CYP21A2 POMC
22 duodenal somatostatinoma 10.6 INS SST
23 glucagonoma 10.6 GHRH SST
24 gigantism 10.6 GHRH PRL
25 melancholia 10.6 CRH PRL
26 postgastrectomy syndrome 10.6 INS SST
27 cytochrome p450 oxidoreductase deficiency 10.6 CYP21A2 POMC
28 postural hypotension 10.6 INS SST
29 pituitary carcinoma 10.6 CRH POMC PRL SST
30 nelson syndrome 10.5 CRH POMC PRL SST
31 adrenal cortex disease 10.5 CRH POMC PRL SST
32 pylorospasm 10.5 HTR4 SST
33 diabetes insipidus, neurohypophyseal 10.5 GNRH1 POMC PRL
34 burns 10.5 CRH INS
35 pancreas disease 10.5 INS POMC SST
36 organ system benign neoplasm 10.5 POMC PRL SST TRH
37 pituitary adenoma, prolactin-secreting 10.5 POMC PRL SST TRH
38 glucose metabolism disease 10.5 INS POMC SST
39 adrenal cortical hypofunction 10.5 CRH CYP21A2 POMC
40 urinary system disease 10.4 CRH INS POMC
41 hypoadrenocorticism, familial 10.4 CRH CYP21A2 POMC
42 adrenal carcinoma 10.4 CRH CYP21A2 POMC
43 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 10.4 CYP21A2 NNT POMC
44 pituitary infarct 10.4 GNRH1 POMC PRL SST
45 chiasmal syndrome 10.4 GNRH1 POMC PRL SST
46 laryngeal tuberculosis 10.3 CD59 POMC
47 hypoadrenalism 10.3 CRH POMC
48 premenstrual tension 10.3 CRH GNRH1 POMC PRL
49 hyperinsulinemic hypoglycemia, familial, 2 10.3 INS SST
50 empty sella syndrome 10.3 GNRH1 POMC PRL TRH

Graphical network of the top 20 diseases related to Pituitary-Dependent Cushing's Disease:



Diseases related to Pituitary-Dependent Cushing's Disease
Sources

Symptoms & Phenotypes for Pituitary-Dependent Cushing's Disease

About this section

MGI Mouse Phenotypes related to Pituitary-Dependent Cushing's Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 APEX1 GHRH CD59 CRH GNRH1 HSD11B1
2 endocrine/exocrine gland MP:0005379 10.18 APEX1 GHRH CD59 CRH GNRH1 HSD11B1
3 growth/size/body region MP:0005378 10.15 GHR APEX1 GHRH GNRH1 CRH HSD11B1
4 behavior/neurological MP:0005386 10.13 GHR CRH HSD11B1 SERPINA6 INS SST
5 immune system MP:0005387 10.03 APEX1 GHRH CRH GNRH1 HSD11B1 GHR
6 adipose tissue MP:0005375 10 CRH HSD11B1 HTR4 GHR INS MC3R
7 liver/biliary system MP:0005370 9.9 GHRH CRH GNRH1 HSD11B1 CYP27A1 GHR
8 nervous system MP:0003631 9.73 GHRH CRH GNRH1 HSD11B1 CYP27A1 HTR4
9 renal/urinary system MP:0005367 9.23 CD59 CRH GNRH1 CYP27A1 GHR SERPINA6
Sources

Drugs & Therapeutics for Pituitary-Dependent Cushing's Disease

About this section

Drugs for Pituitary-Dependent Cushing's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
2
Liraglutide Approved Phase 4 204656-20-2 44147092
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Zinc Approved, Investigational Phase 4 7440-66-6 23994
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
9 insulin Phase 4
10 Insulin, Globin Zinc Phase 4
11 Dipeptidyl-Peptidase IV Inhibitors Phase 4
12 HIV Protease Inhibitors Phase 4
13 Hypoglycemic Agents Phase 4,Phase 2
14 Incretins Phase 4
15
protease inhibitors Phase 4
16 Sitagliptin Phosphate Phase 4
17
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
18
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
19
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-23-7 5754
20
Cabergoline Approved Phase 3,Phase 2 81409-90-7 54746
21
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
22
Mifepristone Approved, Investigational Phase 3,Phase 2,Not Applicable 84371-65-3 55245
23
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
24 Orange Approved, Nutraceutical Phase 3
25 Epinephryl borate Phase 3,Phase 2,Not Applicable
26 Cortisol succinate Phase 3,Phase 2,Not Applicable
27 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2,Not Applicable
28 Hydrocortisone acetate Phase 3,Phase 2,Not Applicable
29 Adrenocorticotropic Hormone Phase 3,Phase 2,Early Phase 1
30 beta-endorphin Phase 3,Phase 2
31 Melanocyte-Stimulating Hormones Phase 3,Phase 2
32 Pharmaceutical Solutions Phase 3
33 Antiparkinson Agents Phase 3,Phase 2
34 Dopamine Agents Phase 3,Phase 2
35 Dopamine agonists Phase 3,Phase 2
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Contraceptive Agents Phase 3,Phase 2,Not Applicable
38 Contraceptives, Oral Phase 3,Phase 2,Not Applicable
39 Contraceptives, Postcoital Phase 3,Phase 2,Not Applicable
40 Luteolytic Agents Phase 3,Phase 2,Not Applicable
41 Antineoplastic Agents, Hormonal Phase 3,Phase 2
42 Edotreotide Phase 3
43 Gastrointestinal Agents Phase 3,Phase 2
44 Radiopharmaceuticals Phase 3
45
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
46
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
47
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
49
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
4 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
5 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
6 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
7 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
8 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
9 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
10 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
11 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
12 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
13 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
14 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
15 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
16 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
17 Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Unknown status NCT02713776 Phase 2 Pasireotide;Placebo
18 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
19 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
20 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
21 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
22 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
23 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
24 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
25 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
26 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Active, not recruiting NCT02804750 Phase 2 CORT125134
27 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
28 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
29 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
30 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
31 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2 SOM230B
32 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
33 Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease Unknown status NCT02603653 Not Applicable
34 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
35 Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia Unknown status NCT02810496 Not Applicable
36 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
37 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
38 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
39 Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Completed NCT01459237 Early Phase 1 Acthrel
40 Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Completed NCT00001453
41 Examination of Brain Serotonin Receptors in Patients With Mood Disorders Completed NCT00026832
42 Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force Readiness Completed NCT01613001
43 Cushing's Disease Complications Recruiting NCT02568982
44 Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease Recruiting NCT02310269 SOM230
45 Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors Recruiting NCT02543697 Not Applicable
46 Collecting Information About Treatment Results for Patients With Cushing's Syndrome Recruiting NCT03364803
47 Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. Recruiting NCT02651844 Not Applicable Mifepristone
48 An Investigation of Pituitary Tumors and Related Hypothalmic Disorders Recruiting NCT00001595
49 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
50 Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome Recruiting NCT03211624

Search NIH Clinical Center for Pituitary-Dependent Cushing's Disease

Cochrane evidence based reviews: pituitary acth hypersecretion

Sources

Genetic Tests for Pituitary-Dependent Cushing's Disease

About this section
Sources

Anatomical Context for Pituitary-Dependent Cushing's Disease

About this section

MalaCards organs/tissues related to Pituitary-Dependent Cushing's Disease:

41
Pituitary, Brain, Testes
Sources

Publications for Pituitary-Dependent Cushing's Disease

About this section

Articles related to Pituitary-Dependent Cushing's Disease:

(show all 13)
# Title Authors Year
1
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. ( 18957506 )
2009
2
Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing's disease. ( 9150699 )
1997
3
Risk factors and long-term outcome in pituitary-dependent Cushing's disease. ( 8675592 )
1996
4
Failure of hypophysectomy to correct pituitary-dependent Cushing's disease in two patients. ( 3190383 )
1988
5
Corticotrophin-releasing factor-test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing's disease. ( 2820618 )
1986
6
A case of pituitary dependent Cushing's disease with clinical and biochemical features of the ectopic ACTH syndrome. ( 2985302 )
1985
7
Is it possible to diagnose pituitary-dependent Cushing's disease? ( 3000267 )
1985
8
Sodium valproate and metyrapone for pituitary-dependent Cushing's disease. ( 6147673 )
1984
9
Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease. ( 6308029 )
1983
10
Simultaneous bilateral venous sampling for adrenocorticotropin in pituitary-dependent cushing's disease: evidence for lateralization of pituitary venous drainage. ( 6311861 )
1983
11
Remission of pituitary-dependent Cushing's disease after removal of nonneoplastyic pituitary gland. ( 6252859 )
1980
12
Pituitary-dependent Cushing's disease. ( 858043 )
1977
13
Pituitary-dependent Cushing's disease. ( 193608 )
1977
Sources

Variations for Pituitary-Dependent Cushing's Disease

About this section
Sources

Expression for Pituitary-Dependent Cushing's Disease

About this section
Search GEO for disease gene expression data for Pituitary-Dependent Cushing's Disease.
Sources

Pathways for Pituitary-Dependent Cushing's Disease

About this section

Pathways related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 12.92 CRH GHR GHRH GNRH1 HTR4 MC3R
2
Corticotropin-releasing hormone signaling pathway 1
11.47 CRH CYP21A2 POMC
3
Metabolism of steroid hormones 66
Show member pathways
 11.38 CYP21A2 HSD11B1 POMC
4
G alpha (s) signalling events 66
11.19 CRH GHRH HTR4 MC3R POMC
5
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10 CRH POMC
Sources

GO Terms for Pituitary-Dependent Cushing's Disease

About this section

Cellular components related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CD59 CRH GHR GHRH GNRH1 INS
2 extracellular space GO:0005615 9.32 CD59 CRH GHR GHRH GNRH1 INS
3 endosome lumen GO:0031904 9.16 INS PRL

Biological processes related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.81 CRH GHRH GNRH1 HTR4 INS MC3R
2 cell-cell signaling GO:0007267 9.73 GHRH GNRH1 INS POMC SST TRH
3 steroid metabolic process GO:0008202 9.69 CRH CYP21A2 HSD11B1
4 response to ethanol GO:0045471 9.67 CRH GNRH1 TRH
5 female pregnancy GO:0007565 9.61 CRH GNRH1 PRL
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 GHR PRL
7 response to corticosterone GO:0051412 9.46 CRH TRH
8 regulation of appetite GO:0032098 9.4 HTR4 POMC
9 negative regulation of feeding behavior GO:2000252 9.37 INS TRH
10 hormone-mediated apoptotic signaling pathway GO:0008628 9.32 CRH SST
11 regulation of signaling receptor activity GO:0010469 9.17 GHRH GNRH1 INS POMC PRL SST
12 glucocorticoid biosynthetic process GO:0006704 9.13 CRH CYP21A2 HSD11B1

Molecular functions related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.55 APEX1 CYP21A2 CYP27A1 HSD11B1 NNT
2 hormone activity GO:0005179 9.17 CRH GNRH1 INS POMC PRL SST
3 steroid binding GO:0005496 9.13 CYP21A2 HSD11B1 SERPINA6
Sources

Sources for Pituitary-Dependent Cushing's Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....